The iconic rise of Viagra has long been a example of pharmaceutical success, yet its legacy within the broader sector now presents questions about potential returns . Alternative versions are diminishing patent protection , prompting worries that betting on companies closely tied to Viagra's once-dominant influence could be a problematic decision ,